Mira Pharmaceuticals (Mira Pharmaceuticals) Cash And Cash Equivalents : $4.60 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals Cash And Cash Equivalents?

Mira Pharmaceuticals's quarterly cash and cash equivalents increased from Jun. 2023 ($0.03 Mil) to Sep. 2023 ($5.87 Mil) but then stayed the same from Sep. 2023 ($5.87 Mil) to Dec. 2023 ($4.60 Mil).

Mira Pharmaceuticals's annual cash and cash equivalents declined from Dec. 2021 ($2.81 Mil) to Dec. 2022 ($0.35 Mil) but then increased from Dec. 2022 ($0.35 Mil) to Dec. 2023 ($4.60 Mil).

Mira Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Mira Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Cash And Cash Equivalents Chart

Mira Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Cash And Cash Equivalents

2.81

0.35

4.60

Mira Pharmaceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial				0.35	-	0.03	5.87	4.60

Mira Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Mira Pharmaceuticals (NAS:MIRA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Mira Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Mira Pharmaceuticals (Mira Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

K6S:Germany

Address

855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mirapharmaceuticals.com

Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.

Executives

Brian Patrick Mcnulty	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff	director	C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr	director, officer: Executive Chairman	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin	officer: Pres. & Chief Scientific Off.	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez	officer: CFO, Secretary & Treasurer	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll	director	100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Erez Aminov	director, officer: Chief Executive Officer	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173